Abetalipoproteinemia

Abetalipoproteinemia

Introduction

Abetalipoproteinemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipid metabolism characterized by the complete absence of apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, and LDL) in the blood. This leads to severe fat malabsorption, retinal degeneration, neuropathy, and acanthocytosis (abnormal red blood cells). The disease results from mutations in the MTTP gene encoding microsomal triglyceride transfer protein.[@neuroacanthocytosis]

Overview

Abetalipoproteinemia was first described independently by Bassen and Kornzweig in 1950, who reported a patient with malabsorption, retinitis pigmentosa, and acanthocytosis. The disease is extremely rare, with an estimated prevalence of approximately 1 in 1,000,000 individuals worldwide.[@acanthocytosis]

The disorder represents a model for understanding the role of apolipoprotein B and [lipid metabolism](/mechanisms/sphingolipid-metabolism) in neurological and retinal function. Early diagnosis and treatment with fat-soluble vitamin supplementation can prevent or delay the neurological and retinal complications.[^7]

Genetics

Gene Defect

Abetalipoproteinemia

Introduction

Abetalipoproteinemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Abetalipoproteinemia, also known as Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipid metabolism characterized by the complete absence of apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, and LDL) in the blood. This leads to severe fat malabsorption, retinal degeneration, neuropathy, and acanthocytosis (abnormal red blood cells). The disease results from mutations in the MTTP gene encoding microsomal triglyceride transfer protein.[@neuroacanthocytosis]

Overview

Abetalipoproteinemia was first described independently by Bassen and Kornzweig in 1950, who reported a patient with malabsorption, retinitis pigmentosa, and acanthocytosis. The disease is extremely rare, with an estimated prevalence of approximately 1 in 1,000,000 individuals worldwide.[@acanthocytosis]

The disorder represents a model for understanding the role of apolipoprotein B and [lipid metabolism](/mechanisms/sphingolipid-metabolism) in neurological and retinal function. Early diagnosis and treatment with fat-soluble vitamin supplementation can prevent or delay the neurological and retinal complications.[^7]

Genetics

Gene Defect

Abetalipoproteinemia is caused by homozygous or compound heterozygous mutations in the MTTP gene (microsomal triglyceride transfer protein), located on chromosome 4q23. This gene encodes a protein essential for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine.[@abetalipoproteinemia]

Over 80 pathogenic variants have been identified, including:

• Nonsense mutations (40%)
• Missense mutations (30%)
• Frameshift mutations (15%)
• Splice site mutations (10%)
• Large deletions (5%)

Inheritance Pattern

• Pattern: Autosomal recessive
• Carrier frequency: Approximately 1 in 500 (heterozygote carriers are asymptomatic)
• Consanguinity: Increased frequency in families with consanguinity

Pathophysiology

Normal Lipoprotein Metabolism

Microsomal triglyceride transfer protein (MTP) plays a crucial role in:

Biochemical Consequences

In abetalipoproteinemia, MTP deficiency causes:

| Abnormal Finding | Pathophysiological Consequence |
|-----------------|------------------------------|
| Absent chylomicrons | Fat malabsorption, fat-soluble vitamin deficiency |
| Absent LDL | Reduced [cholesterol](/mechanisms/cerebral-cholesterol-metabolism) delivery to tissues |
| Absent VLDL | Impaired triglyceride transport |
| Acanthocytosis | Altered membrane lipid composition |
| Low vitamin E | Severe antioxidant deficiency in nervous system |

Neurological Damage

The neurological manifestations result from:

• Vitamin E deficiency: Severe deficiency leads to oxidative damage in [neurons](/entities/neurons)[^8]
• Malnutrition: General deficiency of essential fatty acids
• [Cholesterol deficiency](/entities/brain-cholesterol-metabolism): Affects neuronal membrane integrity and function<br>[@delayed]

Clinical Features

Gastrointestinal Manifestations

• Steatorrhea (fatty stools): Present from infancy
• Failure to thrive: Poor weight gain in childhood
• Abdominal distension: Due to fat accumulation
• Gallstones: Early onset, cholesterol type

Ocular Manifestations

| Feature | Onset | Description |
|---------|-------|-------------|
| Retinitis pigmentosa | 10-20 years | Progressive peripheral vision loss |
| Night blindness | 10-15 years | Often first visual symptom |
| Color vision loss | 20-30 years | Blue-yellow deficiency |
| Central vision loss | 30-40 years | Advanced disease |
| Optic atrophy | 30-40 years | Late complication |

Neurological Manifestations

• Peripheral neuropathy: Usually begins in adolescence
• Ataxia: Progressive cerebellar [ataxia](/diseases/friedreichs-ataxia) in 50% of patients
• Muscle weakness: Distal more than proximal
• Reduced reflexes: Particularly ankle jerks
• Sensory loss: Position and vibration sense affected
• Dysarthria: In severe cases
• Cognitive impairment: Usually mild, but can be severe<br>[@thirtythree]

Hematological Findings

• Acanthocytosis: 50-90% of RBCs are acanthotic (spur-shaped)
• Mild hemolytic anemia: Usually asymptomatic
• Low hemoglobin: Can be mild to moderate

Other Features

• Growth retardation: Short stature common
• Hepatosplenomegaly: Fatty liver, sometimes enlarged liver
• Skeletal abnormalities: Lordosis, scoliosis in some cases

Diagnosis

Clinical Presentation

The classic presentation includes:

Laboratory Findings

| Test | Finding |
|------|--------|
| Total cholesterol | Markedly reduced (< 50 mg/dL) |
| LDL cholesterol | Undetectable |
| Triglycerides | Very low (< 10 mg/dL) |
| Apolipoprotein B | Undetectable |
| Vitamin E | Very low (< 1 μg/mL) |
| Vitamin A | Low |
| Vitamin D | Low |
| Vitamin K | Low |
| Liver function tests | May be elevated |

Genetic Testing

• MTTP gene sequencing: Confirms diagnosis
• Family carrier testing: For at-risk relatives

Differential Diagnosis

| Condition | Key Distinguishing Features |
|-----------|---------------------------|
| Familial hypobetalipoproteinemia | Partial deficiency, milder phenotype |
| Chylomicron retention disease | Only chylomicrons affected |
| Celiac disease | Malabsorption but normal lipids |
| Cystic fibrosis | Pancreatic insufficiency, normal lipids |

Treatment

Dietary Management

• Fat restriction: Reduce long-chain triglycerides to 10-15% of calories
• Medium-chain triglycerides (MCT): Provide as alternative fat source (MCT do not require chylomicrons for absorption)
• Low cholesterol diet: Limited benefit but often recommended

Vitamin Supplementation (CRITICAL)

High-dose fat-soluble vitamin supplementation is essential:[^6]

| Vitamin | Daily Dose | Purpose |
|---------|-----------|---------|
| Vitamin E | 100-200 IU/kg | Neuroprotection, antioxidant |
| Vitamin A | 10,000-25,000 IU | Retinal function |
| Vitamin D | 400-1000 IU | Bone health |
| Vitamin K | 5-10 mg | Coagulation |

Vitamin E supplementation has been shown to:

• Slow or prevent neurological deterioration
• Reduce progression of retinitis pigmentosa
• Improve or normalize neurological examinations

Monitoring

• Neurological examination: Every 6 months
• Ophthalmological examination: Annually
• Lipid panel: Every 6-12 months
• Vitamin levels: Every 6 months
• Growth monitoring: In children

Prognosis

With Early Treatment

• Neurological outcome: Generally stable or slowly progressive
• Visual outcome: Retinitis pigmentosa still progresses but may be slower
• Life expectancy: Near normal with appropriate treatment
• Quality of life: Good with treatment compliance

Without Treatment

• Neurological: Progressive ataxia, neuropathy, disability
• Visual: Progressive blindness
• Prognosis: Significant disability by age 30-40<br>[^6]

Heterozygote Carriers

• Prevalence: Approximately 1 in 250-500
• Lipid profile: Mildly reduced LDL and cholesterol (not clinically significant)
• Health implications: No increased risk of disease
• Reproductive counseling: Important for family planning

Research Directions

Current Investigations

Conclusion

Abetalipoproteinemia is a rare but well-characterized metabolic disorder that serves as an important model for understanding lipoprotein metabolism and its role in neurological and retinal health. The disease highlights the critical importance of fat-soluble vitamins, particularly vitamin E, in maintaining neuronal and retinal function. With early diagnosis and aggressive vitamin supplementation therapy, patients can achieve near-normal life expectancy and quality of life. Ongoing research into gene therapy and MTP modulators offers hope for future treatments that may directly address the underlying metabolic defect. The identification of over 80 pathogenic MTTP variants has improved diagnostic capabilities and enables targeted genetic counseling for affected families.

See Also

• [Apolipoprotein B](/proteins/apolipoprotein-b) - Key lipoprotein in lipid transport
• [Friedreich's Ataxia](/diseases/friedreichs-ataxia) - Hereditary ataxia with similar features
• [Cholesterol Metabolism](/mechanisms/cerebral-cholesterol-metabolism) - Lipid metabolism pathways
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) - Neurodegenerative disorder with autonomic failure
• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia) - Group of ataxia disorders

External Links

• [National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov)
• [Foundation for Retinal Research](https://www.retinalresearch.org)
• [NORD: Abetalipoproteinemia](https://rarediseases.org/rare-/diseases/abetalipoproteinemia/)
• [OMIM: Abetalipoproteinemia](https://www.omim.org/entry/200100)
• [GeneReviews: Abetalipoproteinemia](https://www.ncbi.nlm.nih.gov/books/NBK1311/)

Background

The study of Abetalipoproteinemia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Neuroacanthocytosis.](https://pubmed.ncbi.nlm.nih.gov/32809602/) (2026 Jan) -
• [Acanthocytosis.](https://pubmed.ncbi.nlm.nih.gov/31747195/) (2026 Jan) -
• [Abetalipoproteinemia.](https://pubmed.ncbi.nlm.nih.gov/30020727/) (2026 Jan) -
• [Delayed Tricep Repair Using Dermal Allograft: Technique and Case Examples.](https://pubmed.ncbi.nlm.nih.gov/40642817/) (2025 Sep 1) - Techniques in hand & upper extremity surgery
• [Thirty-Three Years Follow-Up of a Greek Family with Abetalipoproteinemia: Absence of Liver Damage on Long-Term Medium Chain Triglycerides Supplementation.](https://pubmed.ncbi.nlm.nih.gov/40863416/) (2025 Aug 4) - Journal of personalized medicine

References